Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

NCT02198209 on ClinicalTrials.gov · last registry update 2019-09-30

Withdrawn before anyone was enrolled. Its estimated completion date, July 2020, has passed with no update to the record. Primary outcome, as filed: Liver glucokinase activity (acute effect). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Cedars-Sinai Medical Center
Sponsor type: Other
Enrollment: 0
Started: 2019-12
Primary completion: 2020-07 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Liver glucokinase activity (acute effect)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.